MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Next-generation profiling to identify the molecular etiology of Parkinson’s disease dementia

    E.D. Driver-Dunckley, J. Corneveaux, D.B. Matt, L. Cuyugan, W. Liang, M. Huentelman, T.G. Beach, C.H. Adler, A. Henderson-Smith, T. Dunckley (Scottsdale, AZ, USA)

    Objective: To identify novel gene regulatory events associated with Parkinson's disease with dementia (PD-D). Background: PD-D is associated with the spread of degenerative pathology to…
  • 2016 International Congress

    Longitudinal evaluation of motor and non motor symptoms among LRRK2 risk variants

    E.W. Lim, X. Deng, H.H. Li, P. Kumar M, Y.L. Ng, Y.L. Lo, E.K. Tan (Singapore, Singapore)

    Objective: To evaluate the clinical characteristics and progression of Parkinson's disease (PD) in patients with Asian-related LRRK2 variants, G2385R, R1628P and S1647T. Methods: A total…
  • 2016 International Congress

    Human, fly and cellular models of riboflavin transporter neuronopathy

    A. Manole, A. Pandraud, M.M. Reilly, J.E.C. Jepson, H. Houlden (London, United Kingdom)

    Objective: A) To find the spectrum of defects in riboflavin transporter genes; B) To ascertain the in-vitro cellular effects of SLC52A2 mutations and riboflavin on…
  • 2016 International Congress

    Comparison of two protocols for neural induction and cultivation of iPSCs derived neural stem cells

    M.G. Pauly, P. Capetian, B. Meier, V. Krajka, F. Stengel, P. Seibler, C. Klein (Lübeck, Germany)

    Objective: Our objective was to establish and evaluate a protocol for deriving proliferative neural cultures from induced pluripotent stem cells (iPSC). Background: For generating patient…
  • 2016 International Congress

    Influence of levodopa on functional brain connectivity in Parkinson’s disease

    S. Kobayashi, K. Asano, N. Matsuda, H. Kubo, M. Abe, Y. Ugawa (Fukushima-shi, Japan)

    Objective: To evaluate how functional connectivity estimated by resting-state functional magnetic resonance imaging (rs-fMRI) is influenced by levodopa and associated with clinical symptoms in Parkinson's…
  • 2016 International Congress

    Speed and severity of toxicity induced by pre-formed α-synuclein fibrils in rat brain is enhanced by α-synuclein overexpression

    P. Thakur, L. Breger, B. Mattsson, K. Luk, V.M. Lee, J. Trojanowski, A. Björklund (Lund, Sweden)

    Objective: To develop a physiologically relevant model of PD. Background: Intracerebral injection of pre-formed α-synuclein fibrils has emerged as an interesting tool to induce PD-like…
  • 2016 International Congress

    The kinase Fyn mediates levodopa induced dyskinesias in Parkinson´s disease

    J.E. Ferrario, S. Sanz-Blasco, M. Bordone, A. Damianich, A. Bernardi, G. Gomez, I. Taravini, E. Avale, O. Gershanik (Buenos Aires, Argentina)

    Objective: To pharmacologically manipulate the kinase Fyn as a novel target to control levodopa induced dyskinesias. Background: The management of levodopa induced dyskinesias (LID) in…
  • 2016 International Congress

    Olfaction and gray matter volume in Parkinson’s disease. A voxel-based morphometry study

    K. Witt, N. Schmidt, O. Granert, L. Paschen, S. Wolff, G. Deuschl (Kiel, Germany)

    Objective: To evaluate the relation between olfactory functioning and gray matter (GM) volume in patients with Parkinson's disease (PD). Background: Olfactory impairment is one of…
  • 2016 International Congress

    A novel C. elegans model for identification of small molecules that target alpha-synuclein-mediated toxicity

    L.V. Kalia, K. Menezes, Y. Zhang, S. Ishikura, N. Tran, H. Chau, A.M. Lozano, S.K. Kalia, J.G. Culotti, S. Suo, W.S. Ryu (Toronto, ON, Canada)

    Objective: To develop a novel transgenic C. elegans model to study dopaminergic neurodegeneration mediated by alpha-synuclein. Background: Targeting alpha-synuclein could be a disease-modifying strategy for…
  • 2016 International Congress

    Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease

    J. Varghese, K. Terpstra, S. Chiu, R. Mishra, Y. Bureau (London, ON, Canada)

    Objective: The objective of our study was to characterize the behavioral phenotype of the transgenic LRRK-2 rat in the context of PD model and to…
  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 207
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley